Clinical significance of serum interleukin-6 levels in patients with chronic kidney disease
DOI:
https://doi.org/10.15584/ejcem.2024.3.13Keywords:
blood pressure, body mass index, chronic kidney disease, estimated glomerular filtration rate, interleukin, obesityAbstract
Introduction and aim. Elevated levels of interleukin-6 (IL-6) in serum and kidney tissues are associated with the development and progression of chronic kidney disease (CKD). Although the role of pro-inflammatory cytokines, such as IL-6, in the development of cardiovascular complications is well studied, the relationship between serum IL-6 levels and CKD markers remains unclear. This study investigated the clinical significance of serum IL-6 levels in patients with CKD.
Material and methods. Participants were divided into two groups based on estimated glomerular filtration rate (eGFR): group 1 (n=86) with eGFR >60 mL/min and group 2 (n=74) with eGFR <60 mL/min. The CKD Epidemiology Collaboration equation was used to calculate eGFR from serum creatinine and cystatin C levels to assess CKD severity.
Results. Systolic blood pressure was higher in Group 2 than in Group 1 (138±22 mmHg vs. 129±19 mmHg; p<0.05). Serum IL-6 levels were also higher in group 2 (3.095 [interquartile range: 1.528–6.547] pg/mL) than in group 1 (1.711 [interquartile range: 0.920– 3.342] pg/mL; p <0.05). Serum IL-6 levels were strongly correlated with eGFR in multivariable-adjusted linear regression analysis.
Conclusion. IL-6 levels increased in patients with CKD with an eGFR <60 mL/min, and this increase was associated with eGFR and diastolic blood pressure.
Downloads
References
Durlacher-Betzer K, Hassan A, Levi R, et al. Interleukin-6 contributes to the increase in fibroblast growth factor 23 expression in acute and chronic kidney disease. Kidney Int. 2018;94(2):315-325. doi: 10.1016/j.kint.2018.02.026
Rops ALWMM, Jansen E, van der Schaaf A, et al. Interleukin-6 is essential for glomerular immunoglobulin A deposition and the development of renal pathology in Cd37-deficient mice. Kidney Int. 2018;93(6):1356-1366. doi: 10.1016/j.kint.2018.01.005
Boswell RN, Yard BA, Schrama E, et al. Interleukin 6 production by human proximal tubular epithelial cells in vitro: analysis of the effects of interleukin-1 alpha (IL-1 alpha) and other cytokines. Nephrol Dial Transplant. 1994;9(6):599-606. doi: 10.1093/ndt/9.6.599
Naka T, Nishimoto N, Kishimoto T. The paradigm of IL-6: from basic science to medicine. Arthritis Res. 2002;4(3):233-242. doi: 10.1186/ar565
Akira S, Taga T, Kishimoto T. Interleukin-6 in biology and medicine. Adv Immunol. 1993;54:1-78. doi: 10.1016/s0065-2776(08)60532-5
Akchurin O, Patino E, Dalal V, et al. Interleukin-6 Contributes to the Development of Anemia in Juvenile CKD. Kidney Int Rep. 2018;4(3):470-483. doi: 10.1016/j.ekir.2018.12.006
Hénaut L, Massy ZA. New insights into the key role of interleukin 6 in vascular calcification of chronic kidney disease. Nephrol Dial Transplant. 2018;33(4):543-548. doi: 10.1093/ndt/gfx379
Scarpioni R, Obici L. Renal involvement in autoinflammatory diseases and inflammasome-mediated chronic kidney damage. Clin Exp Rheumatol. 2018;36 Suppl 110(1):54-60.
Pecoits-Filho R, Heimbürger O, Bárány P, et al. Associations between circulating inflammatory markers and residual renal function in CRF patients. Am J Kidney Dis. 2003;41(6):1212-1218. doi: 10.1016/s0272-6386(03)00353-6
Held C, White HD, Stewart RAH, et al. Inflammatory Biomarkers Interleukin-6 and C-Reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial. J Am Heart Assoc. 2017;6(10):e005077. doi: 10.1161/JAHA.116.005077
Ridker PM, Rifai N, Stampfer MJ, et al. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation. 2000;101(15):1767-1772. doi: 10.1161/01.cir.101.15.1767
Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296-1305. doi: 10.1056/NEJMoa041031
National Kidney Foundation. KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update. Am J Kidney Dis. 2012;60:850-886. doi: 10.1053/j.ajkd.2012.07.005
Inker LA, Schmid CH, Tighiouart H, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med. 2012;367:20-29. doi: 10.1056/NEJMoa1114248
Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71(6):1269-1324. doi: 10.1161/HYP.0000000000000066
Roos JF, Doust J, Tett SE, Kirkpatrick CM. Diagnostic accuracy of cystatin C compared to serum creatinine for the estimation of renal dysfunction in adults and children--a meta-analysis. Clin Biochem. 2007;40(5-6):383-391. doi: 10.1016/j.clinbiochem.2006.10.026
Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis. 2002;40(2):221-226. doi: 10.1053/ajkd.2002.34487
Zoccali C, Vanholder R, Massy ZA, et al. The systemic nature of CKD. Nat Rev Nephrol. 2017;13(6):344-358. doi: 10.1038/nrneph.2017.52
Gupta J, Mitra N, Kanetsky PA, et al. Association between albuminuria, kidney function, and inflammatory biomarker profile in CKD in CRIC. Clin J Am Soc Nephrol. 2012;7:1938-1946. doi: 10.2215/CJN.03500412
Upadhyay A, Larson MG, Guo CY, et al. Inflammation, kidney function and albuminuria in the Framingham Offspring cohort. Nephrol Dial Transplant. 2011;26:920-926. doi: 10.1093/ndt/gfq471
Su H, Lei CT, Zhang C. Interleukin-6 signaling pathway and its role in kidney disease: an update. Front Immunol. 2017;8:405. doi: 10.3389/fimmu.2017.00405
Feigerlová E, Battaglia-Hsu SF. IL-6 signaling in diabetic nephropathy: from pathophysiology to therapeutic perspectives. Cytokine Growth Factor Rev. 2017;37:57-65. doi: 10.1016/j.cytogfr.2017.03.003
Barreto DV, Barreto FC, Liabeuf S, et al. Plasma interleukin-6 is independently associated with mortality in both hemodialysis and pre-dialysis patients with chronic kidney disease. Kidney Int. 2010;77(6):550-556. doi: 10.1038/ki.2009.503
Murkamilov IT, Sabirov IS, Fomin VV, et al. Correlations between parameters of central hemodynamics and cytokine profile in chronic kidney disease in combination with cerebrovascular diseases. Zh Nevrol Psikhiatr Im S S Korsakova. 2019;119(6):65-71. doi: 10.17116/jnevro201911906165
Abdelnabi AM, Sadek AM. Role of interleukin 6 and highly sensitive C-reactive protein in diabetic nephropathy. Egypt J Intern Med. 2018;30:103-109. doi: 10.4103/ejim.ejim_27_18
Klein B, Zhang XG, Lu ZY, et al. Interleukin-6 in human multiple myeloma. Blood. 1995;85(4):863-872.
Aitbaev KA, Murkamilov Ilkhom T, Fomin VV, et al. Inflammation in chronic kidney disease: sources, consequences and anti-inflammatory therapy. Klin Med (Mosk). 2018;96(4):314-320. doi: 10.18821/0023-2149-2018-96-4-314-320
Gupta J, Mitra N, Kanetsky PA, et al. Association between albuminuria, kidney function, and inflammatory biomarker profile in CKD in CRIC. Clin J Am Soc Nephrol. 2012;7(12):1938-1946. doi: 10.2215/CJN.03500412
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 European Journal of Clinical and Experimental Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.
All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.
